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enrolled in a prospective randomized trial (MAIN, EUDRACT
2008-007004-29). After 48 weeks of cART, we documented a
reduction in activated B cells and CD8+ T cells. Natural killer
cell and dendritic cell frequencies were measured and a decrease
in CD16+ CD56dim with a reciprocal rise in CD56high natural
killer cells and an increase in myeloid and plasmacytoid dendritic
cells were recorded. In conclusion, 48 weeks of cART during
PHI showed signiﬁcant beneﬁts for both innate and adaptive
immunity.
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M. Ripa and M. Pogliaghi contributed equally to this work.During primary human immunodeﬁciency virus (HIV) infection
(PHI) the huge amount of viral replication harms the immune
system through a direct viral cythopathic effect, but mostly
through massive T-cell activation [1,2], causing severe CD4+ T-
cell depletion. Combined antiretroviral therapy (cART) can
only partially restore this damage [3].
Few authors have reported the dynamics of adaptive and
innate immunity during PHI, the effect of early initiation of
cART and the impact on CD4+ T-cell recovery. It has been
shown that not only the T-cell compartment [3,4] but even the
B-cell [5–8], natural killer (NK) cell [9,10] and dendritic cell
(DC) [11] compartments are deranged after PHI. Administra-
tion of cART can improve, but not completely reverse, these
impairments.
This study aims to evaluate T-cell, B-cell, NK cell and DC
subsets during PHI and to assess the effect of cART on the
adaptive and innate immune system.
We analysed 19 patients treated during PHI enrolled in a
monocentre, randomized, open-label, proof-of-concept clinical
trial (MAIN study, EUDRACT number: 2008-007004-29). Pa-
tients started a protease-inhibitor-based regimen and were
randomized to maraviroc as the associated drug. Blood was
collected at baseline (BL), and at week 48 (W48) and processed
to preserve frozen peripheral blood mononuclear cells.
Staining and polychromatic ﬂow cytometry were performed
on cryopreserved peripheral blood mononuclear cells at BL and
W48. Gating strategies are described in Fig. 1. CD8+ and CD4+
T cells were deﬁned as naive, central memory (CM), effector
memory (EM) and terminally differentiated (TD) on the basis of
CCR7 and CD45RA expression; activated cells were deﬁned by
HLA-DR expression. Regulatory T cells were deﬁned as CD4+
CD8–CD25bright FoxP3+ CD127–. B cells were divided into
transitional (TR), naive, resting memory (RM), activated mem-
ory (AM) and tissue-like memory (TLM) on the basis of CD27
and CD21 expression. Plasma cells (PC) were deﬁned as
CD27+ CD38+; NK cells were divided into CD56high and
CD56dim CD16+ subsets. Among DCs, CD11c+ myeloid
(mDCs) and CD123+ plasmacytoid (pDCs) cells were
identiﬁed.Diseases. Published by Elsevier Ltd. All rights reserved
FIG. 1. Gating strategies. (a) T cells; (b) regulatory T cells; (c), B cells; (d), natural killer cells; (e) dendritic cells. Abbreviations: FSC, forward scatter; SSC, side scatter; NV, naive; CM, central memory; EM,
effector memory; TD, terminally differentiated; TR, transitional; RM, resting memory; AM, activated memory; TLM, tissue-like memory; PC, plasma cells; pDC, plasmacytoid dendritic cells; mDC, myeloid
dendritic cells.
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TABLE 1. Baseline characteristicsa
Characteristics (n [ 19)
Age (years), median (IQR) 39 (33–41)
Sex
Male 18 (95%)
Female 1 (5%)
Risk factor
MSM 12 (63%)
Heterosexuals 7 (37%)
Fiebig stage
III 7 (37%)
IV 1 (5%)
V 11 (58%)
Week 0 Week 48
CD4+ T cells (cells/μL) 382 (269–470) 705 (614–854)
CD4+ T cells (%) 12.7 (10.1–22.1) 35.2 (32.2–39.3)
CD8+ T cells (cells/μL) 1539 (884–2697) 733 (587–1263)
CD8+ T cells (%) 70.7 (53.0–72.9) 36.7 (32.7–45.1)
CD4: CD8 ratio 0.20 (0.15–0.42) 1.01 (0.72–1.13)
HIV-RNA (log10 copies/mL) 5.8 (5.2–6.4) 0.0 (0.0–1.6)
Abbreviations: F, female; M, male; MSM, men who have sex with men.
aData are given as n (%) or as median (IQR).
876.e3 Clinical Microbiology and Infection, Volume 21 Number 9, September 2015 CMIAn intention-to-treat analysis was performed. Results are
given as median (interquartile range (IQR)) or frequency (%).
Wilcoxon signed-rank test and Spearman rank correlation co-
efﬁcient were applied. All tests were two-sided and a p value
<0.05 was considered signiﬁcant. Statistical analysis was per-
formed using SPSS 20 (IBM, Chicago, IL, USA).
Patients’ BL characteristics are shown in Table 1. Median
HIV-RNA load was 5.8 log10 copies/mL (IQR 5.2–6.4), and
CD4: CD8 ratio was very low (0.2, IQR 0.15–0.42), mainly
because of massive CD8+ T-cell activation.
After 48 weeks of cART, CD4+ T-cell signiﬁcantly increased
(349 cell/μL, IQR 241–398, p < 0.001), whereas HIV-RNA
decreased (−5.8 log10 copies/mL, IQR −6.4 to −5.2,
p < 0.001), reaching <50 copies/mL in 18 of 19 patients.
At W48, among CD4+ T cells we observed a decrease of
naive and CM cells (naive: −18.1%, IQR −29.9 to −8.0;
CM: −28.9%, IQR −41.5 to −21.6, p < 0.001) and an increase in
TD cells (62.5%, IQR 40.3–70.1, p < 0.001); among CD8+ T
cells, we documented an increase in EM cells (20.8%, IQR −10.6
to 32.7, p 0.030) and TD cells (9.7%, IQR 3.5–20.4, p 0.005).
Cell activation was measured in both CD4+ and CD8+ T
cells. Although CD4+ HLA-DR+ T cells did not signiﬁcantly
change (p 0.053), we found a signiﬁcant reduction in activated
CD8+ T cells (−45.2%, IQR −55.4 to −30.1, p < 0.001).
At baseline, both CD4+ HLA-DR+ and CD8+ HLA-DR+ T
cells were inversely correlated with CD4: CD8 ratio
(r = −0.505, p 0.027 and r = −0.728, p < 0.001, respectively). At
W48 a greater reduction in CD4+ HLA-DR+ T cells was
associated with a higher gain of CD4+ T cells (r = −0.460, p
0.048).
The regulatory T-cell population frequency did not signiﬁ-
cantly change after 48 weeks of treatment (p 0.091).
The analysis of the B-cell populations revealed a 48-week
decrease in activated subsets, TLM cells, AM cells and PCClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect(TLM: −7.1%, IQR −10.5 to −3.0, p < 0.001; AM: −5.2%,
IQR −15.8 to −3.3, p < 0.001; PC: −8.7%, IQR −13.0 to −2.2,
p < 0.001), and an increase in RM cells (9.9%, IQR 7.5–17.4,
p < 0.001).
At baseline, CD4: CD8 ratio inversely correlated with AM
and TLM cells (r = −0.571, p 0.011 and r = −0.715, p 0.001,
respectively), whereas higher HIV-RNA was associated with
higher PC frequencies (r = 0.519, p 0.023). Notably, after 48
weeks a greater reduction of HIV-RNA was associated with a
more signiﬁcant decrease of PC (r = 0.647, p 0.003).
Among NK cells, at W48 we observed a decrease in CD16+
CD56dim (−9.3%, IQR −18.4 to 2.9, p 0.011) and an increase in
CD56high cells (0.4%, IQR −0.2 to 1.0, p 0.033).
Finally, both pDC and mDC percentages increased at W48
(pDC: 0.1%, IQR 0.1–0.2, p 0.001; mDC: 0.2%, IQR 0.1–0.3, p
0.003).
The aims of this study were to assess alterations of innate
and adaptive immunity during PHI and to evaluate the impact of
cART on different cellular subsets. Antiretroviral therapy was
able to decrease CD8+ T-cell activation in patients with PHI,
whereas no effect was documented on CD4+ HLA-DR+ T cells.
A greater decrease of CD4+ HLA-DR+ was correlated to a
more signiﬁcant increase in CD4+ T cells, but no relationships
were found between decrease in CD8+ HLA-DR+ T cells and
CD4+ T-cell gain. Interestingly, we observed a decrease in naive
and CM CD4+ T cells, coupled with an increase in TD CD4+
and CD8+ T cells, in contrast to what is described in chronically
infected patients [12].
Few reports described B-cell kinetics in PHI [13–15].
Notably, at the onset of infection we observed increased fre-
quencies of activated B cells. Dysregulated B-cell subsets, such
as TLM cells, AM cells and PC, decreased signiﬁcantly at W48,
suggesting a possible role of cART in preserving humoral im-
munity. Moreover, we documented a signiﬁcant increase in RM
B cells, responsible for an efﬁcient secondary immune
response.
We also studied some parameters to assess the innate im-
munity in patients treated during PHI: a reciprocal variation of
CD16+ CD56dim and CD56high NK cells was observed, whereas
among DC we documented an increase in both mDCs and
pDCs, usually reduced during Cronic HIV Infection [16].
We showed that during PHI a lower CD4: CD8 ratio was
signiﬁcantly associated not only with more signiﬁcant CD4+ and
CD8+ T-cell activation, but also with higher levels of B-cell
dysregulated subsets, such as AM and TLM. This ﬁnding un-
derlines the importance of the CD4: CD8 ratio as a surrogate
marker of immune function during HIV infection.
Despite the small sample size, because of the well-known
under-estimated incidence of patients diagnosed during
PHI, our study showed that during PHI both the adaptive andious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 876.e1–876.e4
CMI Ripa et al. Adaptive and innate immunity in primary HIV infection 876.e4the innate immune system cell subsets were skewed toward
an activated phenotype. Immune activation was signiﬁcantly
dampened by cART, in particular for CD8+ T cells, B cells
and NK cells. Moreover, our ﬁndings suggested that the
CD4: CD8 ratio could be a useful parameter to indirectly
assess baseline immune activation during primary HIV
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